Health Care [ 5/12 ] | Pharmaceuticals [ 33/74 ]
NASDAQ | Common Stock
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases.
Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 4, 25 | -0.55 Decreased by -885.71% | -0.59 Increased by +6.78% |
| Nov 7, 24 | -1.07 Decreased by -456.67% | -0.92 Decreased by -16.94% |
| Aug 8, 24 | -0.73 Decreased by -335.48% | -0.73 |
| May 9, 24 | -0.12 Decreased by -700.00% | -0.01 Decreased by -1.10 K% |
| Feb 22, 24 | 0.07 Increased by +110.77% | 0.23 Decreased by -69.57% |
| Nov 9, 23 | 0.30 Increased by +132.61% | 0.44 Decreased by -31.82% |
| Aug 10, 23 | 0.31 Increased by +133.33% | 0.10 Increased by +210.00% |
| May 11, 23 | 0.02 Increased by +102.15% | -0.24 Increased by +108.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | -665.00 K Decreased by -100.61% | -37.55 M Decreased by -893.62% | Increased by +5.65 K% Increased by +129.32 K% |
| Sep 30, 24 | 416.00 K Decreased by -99.59% | -72.70 M Decreased by -447.98% | Decreased by -17.48 K% Decreased by -86.00 K% |
| Jun 30, 24 | -1.02 M Decreased by -101.04% | -72.70 M Decreased by -429.35% | Increased by +7.11 K% Increased by +31.52 K% |
| Mar 31, 24 | 88.64 M Increased by +24.10% | -118.79 M Decreased by -7.65 K% | Decreased by -134.01% Decreased by -6.19 K% |
| Dec 31, 23 | 108.45 M Increased by +395.54% | 4.73 M Increased by +111.08% | Increased by +4.36% Increased by +102.24% |
| Sep 30, 23 | 102.69 M Increased by +29.67 K% | 20.89 M Increased by +138.87% | Increased by +20.35% Increased by +100.13% |
| Jun 30, 23 | 98.22 M Increased by +N/A% | 22.07 M Increased by +140.83% | Increased by +22.47% Decreased by N/A% |
| Mar 31, 23 | 71.43 M Increased by +N/A% | 1.57 M Increased by +103.29% | Increased by +2.20% Decreased by N/A% |